LTR Pharma (ASX:LTP) ROE % Adjusted to Book Value: -8.12% (As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.56
! 1 Warning Sign
View Full Analysis

What is LTR Pharma ROE % Adjusted to Book Value?

LTR Pharma ASX:LTP -4.27% 15 ROE % Adjusted to Book Value is -8.12% as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

LTR Pharma's ROE % for the quarter that ended in Dec. 2025 was -39.48%. LTR Pharma's PB Ratio for the quarter that ended in Dec. 2025 was 4.86. LTR Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -8.12%.

LTR Pharma ROE % Adjusted to Book Value Related Terms

LTR Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for LTR Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma ROE % Adjusted to Book Value Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -3.59 -19.44

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial -9.61 -5.16 -6.06 -11.60 -8.12

ASX:LTP vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, LTR Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where LTR Pharma's ROE % Adjusted to Book Value falls into.


ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma ROE % Adjusted to Book Value Calculation

LTR Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-32.47% / 1.67
=-19.44%

LTR Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-39.48% / 4.86
=-8.12%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -8.12% mean?
LTR Pharma (ASX:LTP) has a ROE % Adjusted to Book Value of -8.12% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's ROE % Adjusted to Book Value too high?
LTR Pharma's current ROE % Adjusted to Book Value is -8.12%. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's ROE % Adjusted to Book Value compare to VRTX and REGN?
LTR Pharma's ROE % Adjusted to Book Value of -8.12% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on LTR Pharma and its competitors. LTR Pharma's current ROE % Adjusted to Book Value is -8.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current ROE % Adjusted to Book Value of -8.12%. The current ROE % Adjusted to Book Value is -8.12%. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current ROE % Adjusted to Book Value is -8.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price